\
&
Contact us
\
&
Contact us
Partnership website: https://www.thcspartnership.eu/
The European Partnership 'Transforming Health & Care Systems' (THCS) pools a critical mass of European, national, and regional and international scientific resources to address more efficiently similar challenges faced by health and care systems in Europe and beyond.
The partnership aims to create new knowledge and scientific evidence but also to co-design new solutions & support their transfer and scale-up across countries and regions.
The THCS consortium is mainly composed of a network of Ministries of Research & Innovation, Research & Innovation Funding Organisations and Ministries of Health or Regional Health & Care Authorities. It gathers partners from 64 organisations established in 23 EU Members States and associated countries.
Flanders is represented in the consortium by the Flanders Innovation & Entrepreneurship (VLAIO). Located in Flanders & interested to participate? Find out more on the dedicated VLAIO webpage.
Who can participate in Flanders? The target group is broad. All Flemish companies (both SMEs and large companies) that want to carry out a challenging and risky R&D project together with foreign companies, healthcare organizations and/or knowledge institutions can submit a project proposal.
The Partnership opened a first call for proposals with focus on 'healthcare of the future' beginning of 2023. The call is now closed and results are expected in Autumn 2023.
In february 2024, THCS launched its second Joint Transnational Call (JTC) for proposals aiming to support the implementation of innovative person-centred health and care models addressing prevention strategies, with the key help of existing IT and digital technologies and services.
You can register to the THCS newsletter here to be kept informed about future opportunities.
Commission services: RTD-HS-PARTNERSHIP@ec.europa.eu
Partnership: info@thcspartnership.eu
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
